Sacramento (PRWEB) February 28, 2013
Today at the State Capitol, Assemblyman Marc Levine (D-San Rafael), in partnership with the California Healthcare Institute (CHI), presented a House resolution recognizing Feb. 28, 2013 as Rare Disease Day.
“On this 30th anniversary of the Orphan Drug Act, we recognize the need for continued incentives for biomedical innovators to bring much needed treatments to patients in need,” Levine said.
It is estimated that there are 7,000 diseases considered rare in the U.S. affecting almost 30 million Americans or about 1 in 10 people. Most rare and ultra-rare diseases have no treatment.
In 1983, Congress enacted the Orphan Drug Act to provide incentives for medical pharmaceutical and product developers to focus on treatments for victims of rare diseases. Since that time, there have been more than 2,700 products studied as possible treatments for rare diseases, and more than 400 of those have been approved by the U.S. Food and Drug Administration. Most of these were for diseases that had no approved treatment.
A disease is considered rare in the U.S. if it affects fewer than 200,000 people. Approximately 50 percent of the people affected by rare diseases are children. Even more prominent are ultra-rare diseases that affect only a few thousand individuals.
Patients with rare diseases and ultra-rare diseases are frequently misdiagnosed or are undiagnosed. Few drug companies conduct research into rare diseases since it is difficult to recover the costs of developing treatments for small, geographically dispersed populations.
BioMarin Pharmaceuticals Inc., based in Novato, Calif., is a pioneer in the area of rare disease research. Dedicated to having a meaningful impact in the lives of underserved patients suffering from diseases that are often ignored, BioMarin has successfully brought four therapies for rare genetic diseases to market. The company ha
Copyright©2012 Vocus, Inc.
All rights reserved